Obesity, Iron Regulation and Colorectal Cancer Risk

Completed · Not applicable

Conditions studied: Colon Inflammation, Iron Malabsorption, Obesity, Diet Modification

In brief

Obesity is an independent risk factor for colorectal cancer (CRC) although the underlying mechanisms have not been elucidated. Dietary nutrients play a key role in both the prevention and promotion of CRC. While iron is an essential nutrient, excess iron is associated with carcinogenesis. Unlike the systemic compartment, the intestinal lumen lacks an efficient system to regulate iron. In conditions when dietary iron malabsorption and intestinal inflammation co-exist, greater luminal iron is associated with increased intestinal inflammation and a shift in the gut microbiota to more pro-inflammatory strains. However, treatments designed to reduce luminal, including diet restriction and chelation, are associated with lower intestinal inflammation and the colonization of protective gut microbes. Obesity is associated with inflammation-induced, hepcidin-mediated, iron metabolism dysfunction characterized by iron deficiency and dietary iron malabsorption. Obesity is also linked to intestinal inflammation. Currently, there is a fundamental gap in understanding how altered iron metabolism impacts CRC risk in obesity. The investigator's objective is to conduct a crossover controlled feeding trial of: 1) a "Typical American" diet with "high" heme/non-heme iron", 2) a "Typical American" diet with "low" iron, and 3) a Mediterranean diet with "high" non heme iron and examine effects on colonic and systemic inflammation and the gut microbiome.

Key facts

Study ID

NCT03548948

Run by

University of Illinois at Chicago

People needed

17

Starts

2015-07-15

Expected to finish

2019-06-30

Last updated by the study team

2019-09-27

Who can join

Age: 55 and older, up to 70. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Self-identify as Hispanic, African American, or Caucasian.
• Meet body mass index (BMI > = 30.0 kg/m2) and C-reactive protein (CRP) criteria (> 2.0 mg/dl)
• Post-menopausal (no menstruation in the past 12 months)
• Weight stable (< 3% weight change in the past 3 months)
• Non-smoker
• No major medical problems
• Have a working phone
• No known allergies, intolerance, medical, secular or religious dietary restrictions

You may not qualify if…

• Chronic constipation (less than three stools per week for several months)
• History or intestinal cancer, inflammatory bowel disease, celiac disease, or malabsorptive bariatric surgery
• Previous intestinal surgery
• H pylori infection or taking H2 blockers (e.g., Zantac, Pepcid) /antacids (e.g., Rolaids) more than 3 times per week
• Significant blood loss or blood donation in past 3 months
• Active gastrointestinal bleed
• Any surgery in the past 3 months
• Hemochromatosis
• Sickle cell disease
• Hereditary polyposis
• Rheumatoid arthritis
• Type I or Type II diabetes
• Smoker
• Antibiotic use in the past 2 months
• Excessive alcohol consumption [> 2 standard alcoholic drinks (12 ounces of beer, 5 ounces of wine, 1 shot of hard liquor) per day]
• Aspirin use >81 mg/day OR >325 mg/every other day
• Regularly taking probiotics, fiber supplements, Orlistat (over the counter brand name: Alli), or steroids (inhaled or oral)

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.